NCT00379132 - 131-I-TM-601 Study in Adults With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2008

Conditions

Breast CancerNon-Small Cell Lung CancerMelanomaColorectal CancerPancreatic CancerProstate AdenocarcinomaGliomaPrimary Solid Tumors

Interventions

DRUG

131-I-TM-601 (chlorotoxin)

"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"

Trial Locations (6)

35294

University of Alabama at Birmingham, Birmingham

49503

Lacks Cancer Center at St. Mary's Health Care, Grand Rapids

60611

Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago

60637

University of Chicago, Chicago

75201

Mary Crowley Medical Research Center, Dallas

02111

Tufts - New England Medical Center, Boston